GST HG 151
Alternative Names: GST HG-151Latest Information Update: 28 Dec 2023
Price :
$50 *
At a glance
- Originator Fujian Cosunter Pharmaceutical; WuXi AppTec
- Developer Fujian Cosunter Pharmaceutical
- Class Hepatoprotectants
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors; P38 mitogen-activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic fatty liver disease
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease(In volunteers, In adults) in China (PO, Tablet)
- 19 May 2022 Fujian Cosunter Pharmaceutical files for patent protection with for GST HG 151 in China, Japan, Europe, South Korea and Canada
- 07 Mar 2022 Phase-I clinical trials in Non-alcoholic fatty liver disease (In adults, In volunteers) in China (PO) (NCT05345964)